Figure 2 | Scientific Reports

Figure 2

From: Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Figure 2

DPYD mutation and clinical course of patient #04 who had good response to chemotherapy with gemcitabine. (a) Sequence of DPYD gene in tumor tissue from patient #04. Width of green and orange bands indicates the forward and reverse read depth, respectively. Red band indicates mutated nucleotide. (b) Clinical course of patient #04 from TUR is shown. GC, gemcitabine/cisplatin; TUR, transurethral resection; CR, complete response; RC, radical cystectomy; No rec., no recurrence.

Back to article page